Please login to the form below

Not currently logged in

GE Healthcare's Graham Higson joins NDA Group

Higson will take up the role of managing director of NDA Advisory Services in January

Consulting group NDA has appointed Graham Higson to lead its regulatory and healthcare technology assessment (HTA) advisory board.

He will join as managing director of NDA Advisory Services in January from GE Healthcare, where he has served as global head of regulatory affairs since the beginning of 2011.

Prior to that he spent five years at AstraZeneca as vice president and head of global regulatory affairs and before that served at Baxter, Synthelabo, CibaGeigy, Sandoz and Pfizer.

“I believe Graham's extensive knowledge and experience, coupled with his in-depth insight into the challenges pharmaceutical companies face in fulfilling new drug development plans, right through to the real-life requirements of HTA, will prove invaluable to our clients and to our expert advisory board,” said Dr Lars-Helge Strömquist, CEO of the NDA Group.

In his new role Higson be located in the UK and will lead an advisory board of prominent ex-members of EU regulatory committees and industry experts located across Europe.

Higson succeeds the former head of NDA's regulatory advisory board, Dave Gilbert, who will retire as managing director later this year. Gilbert will continue to provide advice to NDA's clients on a part time basis as a regular member of the company's advisory board.

9th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...